Skip to main content
OpenTrials
Completed

NCT Number: NCT01220024

Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy

This study will assess pain intensity for the first 72 hrs after after aggravated movement (cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Herniorrhaphy Hernia Hernia, Abdominal Hernia, Inguinal Inguinal Hernia Neurologic Manifestations Pain Pain, Postoperative Pathologic Processes Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Postoperative Complications Postoperative Pain Signs and Symptoms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Bellaire, Texas, 77401, United States

About this study

Inguinal herniorrhaphy is a common surgery; and common surgical methods used include laparoscopic and open placement of synthetic mesh. The use of synthetic mesh can greatly reduce the risk of hernia recurrence regardless of the method used for its placement. Managing postoperative pain and preventing morbidity after open mesh herniorrhaphy remain considerable medical challenges.

Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery.

This study will assess pain intensity after surgery in patients who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Man ≥ 18 years
  • Body mass index (BMI) ≥ 19 and ≤ 40 kg/m2.
  • Has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free technique) to be performed according to standard surgical technique under general anesthesia.

Exclusion criteria

  • Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.
  • Scheduled for bilateral inguinal herniorrhaphy.
  • Undergone a prior herniorrhaphy on the side scheduled for repair.
  • Undergone major surgery within 3 mos of the scheduled herniorrhaphy.
  • Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.
  • Concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).
  • Used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.

Treatment and study plan

Bupivacaine Collagen Sponge

Drug

Drug: Bupivacaine Collagen Sponge

Other names: Bupivacaine Implant

Placebo collagen Sponge

Drug

Drug: Placebo Collagen Sponge

Other names: Collagen Implant

Primary outcomes

  1. Sum of Pain Intensity Defined as Area Under the Curve (AUC) of 100-mm VAS PI Scores.

    Time frame: 1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.

    The primary efficacy variable was SPI defined as area under the curve (AUC) of 100-mm VAS pain intensity scores after aggravated movement (cough) from 1 to 72 hours after surgery. Minimum score is "0". Maximum score is 7200. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. A lower score means a better outcome or less pain reported.

Secondary outcomes

  1. Sum of Pain Intensity (SPI) After Aggravated Movement (Cough)

    Time frame: 1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.

    Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is "0" and the maximum score is 100* the number of hours in that period.

  2. Sum of Pain Intensity (SPI) Using a Visual Analog Scale (VAS) When at Rest

    Time frame: 1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours.

    Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) at each time point. A lower score is better which means the patient experience lower pain. The score is calculated using the number of hours * the VAS score. This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule. For each measure outcome - the minimum score is "0" and the maximum score is 100* the number of hours in that period.

  3. Pain Intensity Visual Analog Pain Scale Scores Over Time After Aggravated Movement (Cough)

    Time frame: 1,2,4,6,8,10,12,24,48 and 72 hours

    Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. The lower the sore the better the outcome. Higher score is a worse outcome

  4. Pain Intensity VAS Scores Over Time at Rest

    Time frame: 1,2,4,6,8,10,12,24,48 and 72 hours

    Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100). Patients were asked during multiple time points to provide a score on this VAS scale. Lower score is better. Higher score means more pain. Time points are summarized independently

  5. Mean Sum of Pain Intensity (SPI) Categorical Scores After Aggravated Movement

    Time frame: 1,2,4,6,8,10,12,24,48 and 72 hours

    Measured on a Visual Analog Pain Scale (VAS) with the lowest possible value of 0 and highest 100 (0 - 100) for each timepoint. (timepoints 1,2,4,6,8,10,12,24,48 and 72 hours ) Patients were asked during multiple time points to provide a score on this VAS scale. For 1 to 24 hours the highest score possible would be 800. For 1 to 48 hours the highest score possible would be 900. For 1 to 72 hours the highest score possible would be 1000. A mean Lower score is better. A mean Higher score is a worse outcome.

Sponsors and collaborators

Lead sponsor

Innocoll

Industry

Collaborators

  • Premier Research

Registry information

Official study title

A Phase II, Randomized, Single Dose, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety Profile of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Open Laparotomy Herniorrhaphy

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Oct 13, 2010
Registry last updated
Mar 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.